Jamjoom Pharmaceuticals Factory Company

SASE:4015 Stock Report

Market Cap: ر.س10.3b

Jamjoom Pharmaceuticals Factory Valuation

Is 4015 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4015 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ر.س119.44
Fair Value
23.2% overvalued intrinsic discount
4
Number of Analysts

Below Fair Value: 4015 (SAR147.1) is trading above our estimate of fair value (SAR119.44)

Significantly Below Fair Value: 4015 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4015?

Key metric: As 4015 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4015. This is calculated by dividing 4015's market cap by their current earnings.
What is 4015's PE Ratio?
PE Ratio23x
Earningsر.س447.34m
Market Capر.س10.30b

Price to Earnings Ratio vs Peers

How does 4015's PE Ratio compare to its peers?

The above table shows the PE ratio for 4015 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.9x
2070 Saudi Pharmaceutical Industries and Medical Appliances
27.4x17.69%ر.س3.5b
4016 Middle East Pharmaceutical Industries
25xn/aر.س2.4b
H02 Haw Par
13.2xn/aS$3.4b
300049 Inner Mongolia Furui Medical Science
150.2x41.33%CN¥18.1b
4015 Jamjoom Pharmaceuticals Factory
23x11.19%ر.س10.3b

Price-To-Earnings vs Peers: 4015 is good value based on its Price-To-Earnings Ratio (23x) compared to the peer average (53.1x).

Price to Earnings Ratio vs Industry

How does 4015's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
4015 23.0xIndustry Avg. 25.1xNo. of Companies74PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4015 is good value based on its Price-To-Earnings Ratio (23x) compared to the Asian Pharmaceuticals industry average (24.9x).

Price to Earnings Ratio vs Fair Ratio

What is 4015's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4015 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23x
Fair PE Ratio33.7x

Price-To-Earnings vs Fair Ratio: 4015 is good value based on its Price-To-Earnings Ratio (23x) compared to the estimated Fair Price-To-Earnings Ratio (33.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4015 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س150.20
ر.س169.63
+12.93%
1.72%ر.س173.00ر.س166.30n/a4
Nov ’26ر.س156.00
ر.س172.24
+10.41%
1.98%ر.س176.75ر.س167.20n/a4
Oct ’26ر.س156.90
ر.س177.39
+13.06%
3.61%ر.س187.00ر.س167.20n/a5
Sep ’26ر.س157.20
ر.س178.41
+13.49%
3.52%ر.س187.00ر.س167.20n/a6
Aug ’26ر.س162.30
ر.س178.20
+9.80%
3.56%ر.س187.00ر.س167.20n/a6
Jul ’26ر.س169.40
ر.س178.20
+5.19%
3.56%ر.س187.00ر.س167.20n/a6
Jun ’26ر.س169.20
ر.س178.20
+5.32%
3.56%ر.س187.00ر.س167.20n/a6
May ’26ر.س170.00
ر.س176.50
+3.82%
4.53%ر.س187.00ر.س165.30n/a6
Apr ’26ر.س156.00
ر.س178.36
+14.33%
4.19%ر.س187.00ر.س165.30n/a5
Mar ’26ر.س174.00
ر.س177.60
+2.07%
3.76%ر.س187.00ر.س169.50n/a5
Feb ’26ر.س163.40
ر.س176.90
+8.26%
3.50%ر.س187.00ر.س169.50n/a5
Jan ’26ر.س152.80
ر.س174.38
+14.12%
2.29%ر.س180.00ر.س169.50n/a4
Dec ’25ر.س156.40
ر.س174.38
+11.49%
2.29%ر.س180.00ر.س169.50n/a4
Nov ’25ر.س169.00
ر.س172.94
+2.33%
3.48%ر.س180.00ر.س163.75ر.س156.004
Oct ’25ر.س185.80
ر.س172.94
-6.92%
3.48%ر.س180.00ر.س163.75ر.س156.904
Sep ’25ر.س177.40
ر.س162.25
-8.54%
9.33%ر.س180.00ر.س143.00ر.س157.203
Aug ’25ر.س155.20
ر.س146.62
-5.53%
5.01%ر.س156.86ر.س140.00ر.س162.303
Jul ’25ر.س144.60
ر.س146.62
+1.40%
5.01%ر.س156.86ر.س140.00ر.س169.403
Jun ’25ر.س132.60
ر.س146.62
+10.57%
5.01%ر.س156.86ر.س140.00ر.س169.203
May ’25ر.س133.00
ر.س142.10
+6.84%
1.05%ر.س143.31ر.س140.00ر.س170.003
Apr ’25ر.س128.80
ر.س132.10
+2.56%
7.22%ر.س143.31ر.س120.00ر.س156.003
Mar ’25ر.س144.40
ر.س118.28
-18.09%
10.80%ر.س133.00ر.س101.85ر.س174.003
Feb ’25ر.س138.60
ر.س118.28
-14.66%
10.80%ر.س133.00ر.س101.85ر.س163.403
Jan ’25ر.س114.60
ر.س118.28
+3.21%
10.80%ر.س133.00ر.س101.85ر.س152.803
Dec ’24ر.س114.00
ر.س118.28
+3.76%
10.80%ر.س133.00ر.س101.85ر.س156.403
Nov ’24ر.س108.40
ر.س115.28
+6.35%
11.84%ر.س134.00ر.س101.85ر.س169.003
ر.س169.63
Fair Value
13.3% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/17 15:27
End of Day Share Price 2025/11/17 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jamjoom Pharmaceuticals Factory Company is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jassim Al-JubranAljazira Capital Company
Madhu AppissaAl Rajhi Capital
null nullAl Rajhi Capital